LENZ Therapeutics is a commercial-stage pharmaceutical company focused on a single product: VIZZ (aceclidine 1.44%), a once-daily prescription eye drop for presbyopia — the age-related near vision loss that affects most adults over 45. VIZZ received FDA approval in July 2025 and launched in the U.S. in late 2025. It is sold on a self-pay basis at $79/month, with no insurance reimbursement. LENZ sells directly to U.S. patients through retail pharmacies and an e-pharmacy partner. Revenue is driven by new prescriptions and monthly refills, with management estimating roughly five refills per year per active user. LENZ's go-to-market strategy targets roughly 15,000 high-volume eye care professionals through an 88-territory (expanding to 117) sales force, complemented by a direct-to-consumer digital campaign launched in Q1 2026. For ex-U.S. markets, LENZ licenses rights to regional partners — including deals covering Greater China, South Korea, Southeast Asia, Canada, and the Middle East — earning upfront payments, milestones, and royalties rather than selling product directly. LENZ outsources all manufacturing to contract manufacturers. The cost structure is heavily weighted toward sales and marketing, with R&D expenses declining sharply post-approval. LENZ holds at least 17 U.S. patents with protection extending to at least 2044, and has five years of FDA data exclusivity expiring July 2030. Longer term, LENZ has indicated interest in adding other ophthalmology products to its portfolio to leverage its existing ECP sales infrastructure.